The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins

DAAN DE GOUW; DIEGO O. SERRA; MARIEN I. DE JONGE; PETER W.M. HERMANS; HANS J.C.T. WESSELS; ALDERT ZOMER; OSVALDO M YANTORNO; DIMITRI A. DIAVATOPOULOS; FRITS R. MOOI

Emerging Microbes and Infections

EMI editorial office 56 Shuidian Road Hong Kou District Shanghai 200083

Lugar: Shanghai ; Año: 2014 vol. 3 p. 58 - 67

Dear Prof Yantorno: Here is a copy of the decision letter for manuscript "The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins" by Frits R. Mooi, Daan de Gouw, Diego O. Serra, Marien I. de Jonge, Peter W.M. Hermans, Hans J.C.T. Wessels, Aldert Zomer, Osvaldo Yantorno, Dimitri A. Diavatopoulos, and Frits R. Mooi [Paper #EMI2014028R1], which you were a Contributing Author. You can now use a single sign-on for all your accounts, view the status of all your manuscript submissions and reviews, access usage statistics for your published articles and download a record of your refereeing activity for the Nature journals. Please check your account regularly and ensure that we have your current contact information. In addition, NPG encourages all authors and reviewers to associate an Open Researcher and Contributor Identifier (ORCID) to their account. ORCID is a community-based initiative that provides an open, non-proprietary and transparent registry of unique identifiers to help disambiguate research contributions. Sincerely, Bin Wang Section Editor Emerging Microbes & Infections ------------------------------------------------------------------------ Subject: Emerging Microbes & Infections-decision on your Original Article EMI2014028R1. 23rd Jun 14 #EMI2014028R1 Dear Prof Mooi, Thank you for your submission of manuscript entitled "The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins" to Emerging Microbes & Infections. I am pleased to inform you that your manuscript has been accepted in its current form for publication in Emerging Microbes & Infections. Your paper is considered to be a significant contribution to the field, and we appreciate the opportunity to publish it in this journal. Since your paper is an Original Article, it may be accompanied upon publication by a Research Summary. The Research Summary will be written by a professional writer and be a 100-150 word synopsis of your article; it will provide concise information to the reader about the aims, main outcomes and significant conclusions of the article. It will be published under a Creative Commons license and with attribution we encourage you to freely use, post and distribute the summary as is appropriate. You will receive the text of the Research Summary with your paper proof, if this is to be supplied. For more information, see http://www.nature.com/emi/marketing/benefits.html. Upon the Editorial Office´s confirmation of the correct file types, your manuscript will be sent to production. Using the link below, please download, print and sign the License to Publish Form and the Open Access Payment Form on behalf of your co-authors, with their consent. Please send these forms as soon as possible to the Editorial Office (editorial@emi2012.org). License to Publish form http://www.nature.com/licenceforms/emi/emi-ltp-cc-by-sa-nd.pdf Open Access payment form http://www.nature.com/licenceforms/emi/emi-apc-form.pdf Thank you again for your contribution and please do not hesitate to contact the Editorial Office (editorial@emi2012.org) if you have any questions about your paper or through the Production process. Sincerely, Bin Wang Section Editor Emerging Microbes & Infections and Shan Lu Deputy Editor-in-Chief If you no longer wish to receive any email correspondence from this journal, please click the link below to unsubscribe Link Not Available If you no longer wish to receive any email correspondence from this journal, please click the link below to unsubscribe http://mts-emi.nature.com/cgi-bin/main.plex?el=A4CU3Ft3C5kh6BX3A9ftdvXG2QnoHbhoRONUDHJrqZAZ This email has been sent through the NPG Manuscript Tracking System NY-610A-NPG&MTS Confidentiality Statement: This e-mail is confidential and subject to copyright. Any unauthorised use or disclosure of its contents is prohibited. If you have received this email in error please notify our Manuscript Tracking System Helpdesk team at http://platformsupport.nature.com . Details of the confidentiality and pre-publicity policy may be found here http://www.nature.com/authors/policies/confidentiality.html Privacy Policy | Update Profile Pertussis is an infectious respiratory disease of humans caused by the Gram-negative pathogen Bordetella pertussis. The use of acellular pertussis vaccines (aPs) which induce Immunity of relative short duration and the emergence of vaccine-adapted strains are thought to have contributed to the recent resurgence of pertussis in industrialized countries despite high vaccination coverage. Current pertussis vaccines consist of antigens derived from planktonic bacterial cultures. However, recent studies have shown that biofilm formation represents an important aspect of B. pertussis infection, and antigens expressed during this stage may therefore be potential targets for vaccination. Here we provide evidence that vaccination of mice with B. pertussis biofilm-derived membrane proteins protects against infection. Subsequent proteomic analysis of the protein content of biofilm and planktonic cultures yielded 11 proteins which were ≥3-fold more abundant in biofilms, of which BipA was the most abundant, surface-exposed protein. As proof of concept, mice were vaccinated with recombinantly produced BipA. Immunization significantly reduced colonization of the lungs and antibodies to BipA were found to efficiently opsonize bacteria. Finally, we confirmed that bipA is expressed during respiratory tract infection of mice, and that anti-BipA antibodies are present in the serum of convalescent whooping cough patients. Together, these data suggest that biofilm proteins and in particular BipA may be of interest for inclusion into future pertussis vaccines.